Matthew Peter Scanlan

US Patent:

6339140, Jan 15, 2002

Filed:

Mar 1, 2001

Appl. No.:

09/796780

Inventors:

Ali O. Gure - New York NY
Ozlem Tureci - Homburg/Saar, DE
Ugur Sahin - Homburg/Saar, DE
Solam Tsang - New York NY
Matthew J. Scanlan - New York NY
Alexander Knuth - Frankfurt am Main, DE
Michael Pfreundschuh - Homburg/Saar, DE
Lloyd J. Old - New York NY
Yao-Tseng Chen - New York NY

Assignee:

Ludwig Institute for Cancer Research - New York NY
Cornell Medical Research Foundation - Ithaca NY
Memorial Sloan Kettering Cancer Center - New York NY

International Classification:

C07K 100

US Classification:

530350, 514 2

Abstract:

The invention relates to members of the SSX family of genes, as well as their uses.

US Patent:

6403373, Jun 11, 2002

Filed:

Jun 22, 1998

Appl. No.:

09/102322

Inventors:

Matthew J. Scanlan - New York NY
Yao-Tseng Chen - New York NY
Elisabeth Stockert - New York NY
Lloyd J. Old - New York NY

Assignee:

Ludwig Institute for Cancer Research - New York NY

International Classification:

C12N 510

US Classification:

435325, 4353201, 536 235

Abstract:

Various molecules associated with cancer are disclosed. The invention also discloses diagnostic and therapeutic methods based upon these molecules.

US Patent:

6440663, Aug 27, 2002

Filed:

Oct 5, 1998

Appl. No.:

09/166350

Inventors:

Matthew J. Scanlan - New York NY
Elisabeth Stockert - New York NY
Yao-Tseng Chen - New York NY
Lloyd J. Old - New York NY
Elke Jager - Frankfurt AM Main, DE
Alex Knuth - Frankfurt AM Main, DE

Assignee:

Ludwig Institute for Cancer Research - New York NY
The New York Hospital-Cornell Medical Center - New York NY

International Classification:

C12Q 168

US Classification:

435 6, 435 911, 435 912, 530300, 536 231

Abstract:

Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in renal cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with renal cancer. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

US Patent:

6448073, Sep 10, 2002

Filed:

Jan 28, 2000

Appl. No.:

09/493914

Inventors:

Dirk Jager - New York NY
Elizabeth Stockert - New York NY
Matthew Scanlan - New York NY
Ali Gure - New York NY
Elke Jager - Frankfurt am Main, DE
Alexander Knuth - Frankfurt am Main, DE
Lloyd Old - New York NY
Yao-tseng Chen - New York NY

Assignee:

Ludwig Institute for Cancer Research - New York NY

International Classification:

C12N 1563

US Classification:

4353201, 4352523, 435325, 435366, 536 231, 536 235, 536 245

Abstract:

The invention relates to isolated, cancer associated antigens, nucleic acid molecules, and various uses thereof.

US Patent:

6517837, Feb 11, 2003

Filed:

Feb 22, 2000

Appl. No.:

09/510543

Inventors:

Matthew J. Scanlan - New York NY 10021
Yao-Tseng Chen - New York NY 10021
Elisabeth Stockert - New York NY 10021
Lloyd J. Old - New York NY 10105

International Classification:

A61K 3900

US Classification:

4241841, 4242271, 530350, 536 231

Abstract:

Various molecules associated with disorders such as cancer are disclosed. The invention also discloses diagnostic and therapeutic methods based upon these molecules, as well as compositions for stimulating an immune response and methods for identifying cancer-associated nucleic acid and polypeptide molecules.

US Patent:

6525177, Feb 25, 2003

Filed:

Dec 29, 2000

Appl. No.:

09/751798

Inventors:

Elisabeth Stockert - New York NY
Elke Jäger - Frankfurt am Main, DE
Yao-tseng Chen - New York NY
Matthew Scanlan - New York NY
Knuth Alexander - Frankfurt am Main, DE
Lloyd J. Old - New York NY

Assignee:

Cornell Research Foundation, Inc. - New York NY
Ludwig Institute for Cancer Research - New York NY
Sloan-Kettering Cancer Center - New York NY

International Classification:

C07K 14435

US Classification:

530350, 530300, 5303871, 536 235

Abstract:

The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.

US Patent:

6686147, Feb 3, 2004

Filed:

Sep 9, 1999

Appl. No.:

09/392714

Inventors:

Matthew J. Scanlan - New York NY
Ali Gure - New York NY
Lloyd J. Old - New York NY
Yao-Tseng Chen - New York NY
Barbara Williamson - New York NY

Assignee:

Ludwig Institute for Cancer Research - New York NY

International Classification:

C12Q 168

US Classification:

435 6, 435 911, 435 912, 435 94, 536 235, 536 243, 536 2431

Abstract:

Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in testis cells using antisera from seminoma patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with a variety of cancers. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

US Patent:

6723832, Apr 20, 2004

Filed:

Oct 2, 1998

Appl. No.:

09/165546

Inventors:

Alexander Knuth - Frankfurt am Main, DE
Elke Jäger - Frankfurt am Main, DE
Yao-tseng Chen - New York NY
Matthew Scanlan - New York NY
Ali Gure - New York NY
Gerd Ritter - New York NY
Lloyd J. Old - New York NY
Jan W. Drijfhout - Leiden, NL

Assignee:

Ludwig Institute for Cancer Research - New York NY
Memorial Sloan-Kettering Cancer Center - New York NY
Academisch Ziekenhuis Leiden - Leiden
Cornell Research Foundation - Ithaca NY

International Classification:

C07K 700

US Classification:

530324, 530325, 530326, 530328, 530350, 514 12, 514 13, 514 15, 514885, 4241851, 424450, 424 851, 424 852, 4242821, 4242831

Abstract:

The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.